Share

Banks see talent flee amid healthcare M&A boom

New York - Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in US healthcare deal activity to seek better compensation at boutique investment banks as well as to participate in the growth of the industry at biotech companies themselves.

JPMorgan Chase & Co and Bank of America have both lost senior healthcare investment bankers to boutique investment bank Guggenheim Partners, showing that banks face challenges in being able to pay competitive rates.

The biggest US banks are under pressure from regulators to preserve more capital, rather than use M&A fees to pay higher bonuses.

"The volume of transactions across healthcare is extreme and so the banker merry-go-round begins," said Paul Heller, the leader of executive recruiting firm Caldwell Partners' financial services practice.

There's been $92.5bn worth of US healthcare merger activity so far this year, 73% more than in the same period last year, driven by 242 deals.

Healthcare has been the busiest sector for deals so far this year, fuelled by transactions such as Pfizer’s $17bn offer for Hospira and Valeant Pharmaceuticals International’s $11bn acquisition of Salix Pharmaceuticals.

US healthcare investment banking fees, meanwhile, have topped $1.9bn since January, up more than 37% from the same period last year.

Average annual pay for a healthcare investment banking managing director - the most typical role for a senior banker - is roughly $1.5m to $2m, according to recruiters and bankers, and hasn't budged much in recent years despite the rise in M&A activity.

Wall Street compensation rose about 4% on average last year, according to financial industry recruiting firm Options Group.

Some large banks are hoping to stem the flow of banker departures by offering one-year pay guarantees for top performers, according to industry bankers.

Guggenheim Partners said in March that Joseph Kohls, a former Bank of America global healthcare co-head and Jeffrey Hoffman, JPMorgan Chase & Co's former West Coast healthcare head, would be joining the firm.

Kohls helped advise medical device company Biomet on its $13.4bn acquisition by Zimmer Holdings last year, and Hoffman led a team that advised AbbVie on its $55bn deal for British pharmaceutical company Shire, which it ended up abandoning.

Bankers can often negotiate a 30 to 50% pay raise for their first-year compensation at a new bank if they jump ship, according to recruiters and bankers.

Free from many of Wall Street's regulations, a boutique investment bank can also offer bankers hefty commissions on individual deals.

Some boutique banks are luring rainmakers with the promise of taking home a large percentage of the fees they generate, bankers and recruiters said, a practice rarely seen at the bigger banks.

Boutiques can also offer their bankers compensation in cash, while a large portion of pay at larger banks remains tied up in stock.

Neither Kohls nor Hoffman responded to requests for comment.

Meanwhile, Goldman Sachs Group banker Lorence Kim left in March 2014 to take a job with life science company Moderna, while his Goldman colleague David Woodhouse joined NGM Biopharmaceuticals in March of this year.
 
Morgan Stanley's Steve Harr took an executive position at Juno Therapeutics in March 2014.

Former Credit Suisse investment banker Mark Page joined biotech Macrocure in February as chief financial officer.

"My whole banking career was to help set me up for an opportunity like this," Page said.
Kim, Woodhouse and Harr all declined to respond to requests for comment.

These bankers may benefit by taking executive roles at biotech companies and receiving stock as part of their compensation, in a bet that the share price will go up. The Nasdaq Biotechnology index has risen 66% in the last 12 months.

"The potential equity upside on the corporate side is as attractive today than it ever has been compared to Wall Street compensation," said Burke St. John, vice chairman and head of the global financial services practice at executive search firm CTPartners.

"It might take you two or three times as long on a more traditional Wall Street career path to earn what you could make working for the right client."

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
18.94
-0.2%
Rand - Pound
23.91
-0.1%
Rand - Euro
20.43
+0.2%
Rand - Aus dollar
12.34
+0.1%
Rand - Yen
0.13
-0.2%
Platinum
910.50
+1.5%
Palladium
1,011.50
+1.0%
Gold
2,221.35
+1.2%
Silver
24.87
+0.9%
Brent Crude
86.09
-0.2%
Top 40
68,346
+1.0%
All Share
74,536
+0.8%
Resource 10
57,251
+2.8%
Industrial 25
103,936
+0.6%
Financial 15
16,502
-0.1%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders